media – Page 173 – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

Survival VS making money! BeiGene will make a profit, Junshi will reduce losses, Chinese medicine and vaccines will decline by 60%, and hundreds of pharmaceutical companies will lose 9 billion?

With the end of 2024, A-shares have also entered the stage of announcing full-year performance. According to statistics from E-Pharmaceutical Manager, as of January 20, in the biopharmaceutical industry, a total of 101 A-share listed companies and 7 Hong Kong-listed companies disclosed performance forecasts. The drama of the strong getting stronger is still being staged in each sub-sector. The Chinese medicine sector, such as Dong-E-E-Jiao, is not only expected to win a net profit of 1.5 billion to 1.6 billion yuan, but also an increase of 30% to 39%; the net profit of the Science and Technology Innovation Board listed company Sansheng Guojian is expected to be 700 million to 712 million yuan, an increase of 137.73% to 162%. In addition, Sinopharm Modern, a chemical pharmaceutical company, Tebao Bio, a biological product company, Synthetic Biology leader Chuan Ning Bio, and orthopedic consumables leader Dabao Medical have also achieved a “double ...
- Source: drugdu
- 278
- January 23, 2025
Net profit attributable to parent company expected to drop by 57% to 67% in 2024

On January 20, 2025, WALVAX, a leading vaccine company in the A-share market, issued an announcement that its operating income is expected to be about 2.86 billion yuan, a sharp drop from 4.114 billion yuan in the same period last year; it is expected that the net profit attributable to parent company in 2024 will be 140 million to 180 million yuan, a decrease of 57% to 67% from 419 million yuan in the same period last year. Net profit after deducting non-recurring gains and losses is expected to be 110 million to 150 million yuan, a decrease of 74% to 81% from 574 million yuan in the same period last year. WALVAX disclosed that the main reasons for the performance changes include: the decline in sales revenue due to the decline in the number of newborns in China and the intensification of market competition. At the same time, in ...
- Source: drugdu
- 251
- January 23, 2025
Nat Immunol | Mechanisms of Durability of Vaccine Antibody Responses

In vaccinology, inducing durable protective immunity is a major challenge. It is generally believed that protection against infection is mainly achieved through antibodies, which prevent host cells from becoming infected. Some live attenuated vaccines (such as smallpox and yellow fever vaccines) induce durable antibody responses that can last a lifetime; however, in other types of vaccines, including inactivated subunit vaccines for seasonal influenza, pertussis vaccines, Salmonella typhi, Neisseria meningitidis vaccines, as well as RTS,S malaria vaccines and some candidate vaccines against HIV, the phenomenon of waning antibody responses has been widely documented. Why some vaccines provide lifelong protection while others only protect for a few months remains a major unsolved mystery in immunology. An adjuvant is a component of a vaccine that enhances the strength and durability of the immune response. For more than 70 years, insoluble aluminum salts (alum) have been the only approved adjuvants. However, the number of ...
- Source: drugdu
- 253
- January 23, 2025
Cambodia Phar-Med Expo

Organiser：Minh Vi Exhibition & Advertisement Services Co., Ltd. Time：September 17 – 19, 2025 Address：Diamond Island, Phnom Penh, Cambodia Exhibition hall：Diamond Island Convention & Exhibition Center Product range: Medical Devices & Equipment: Medical auxiliary equipment, rehabilitation and physiotherapy equipment, medical vehicles, beds, tables, surgical equipment, preventive medicine equipment, diagnostic equipment, monitoring equipment, treatment equipment, laboratory analysis equipment, specialized surgical equipment, emergency and rescue equipment, surgical instruments, diagnostic equipment and supplies, analysis and control, monitoring equipment, orthopedic appliances, ophthalmic instruments and equipment, ENT equipment, dental supplies and equipment, radiological equipment, medical reagents and equipment, prosthetics and rehabilitation equipment, medical health care products and equipment, sterilization equipment, traction and diagnostic equipment, treatment equipment, laboratory analysis equipment, etc. Medical Institutions & Laboratory Technology Equipment: Laboratory furniture, laboratory automation and accessories, optical instruments and equipment, dressings, wound care materials, catheters, medical laboratory analysis and diagnostic instruments, biopharmaceutical instruments, cell biology instruments, laboratory instruments and ...
- Source: drugdu
- 666
- January 23, 2025
Six new drugs will be launched this year, aiming for 20 billion yuan

Innovent Biologics also disclosed multiple drug collaborations and research and development progress on the eve of the conference. Although it did not disclose a time signal to turn losses into profits, it also stated at the conference that its confidence in achieving a domestic product revenue target of 20 billion yuan by 2027 has become increasingly firm based on the upcoming commercialization of multiple drugs. On the morning of January 17th, Innovent Biologics announced the disclosure of its newly introduced third-generation EGFR-TKI lung cancer targeted drug, Aoyi Xin ® (Lirotinib tablets) have been approved for marketing by the National Medical Products Administration. In the early morning of the same day, Yu Dechao, the founder, chairman, and CEO of Innovent Biologics, revealed at the JPM2025 conference that six new drug varieties will be launched in 2025, including three heavyweight products, Masidomide, Pitacizumab, and Tetuximab; We plan to submit new drug applications ...
- Source: drugdu
- 813
- January 22, 2025
Two innovative medical devices enter the special review process

According to the China Medical Device Innovation and Priority Approval Database, two innovative medical devices have entered the special review process in recent public announcements released by local drug regulatory authorities across the country. They are respectively the exercise rehabilitation system of Beijing Tianxing Medical Co., Ltd. (hereinafter referred to as Tianxing Medical) and the disposable angle guided puncture needle of Jiangsu Chunzhen Medical Technology Co., Ltd. (hereinafter referred to as Chunzhen Medical). Tianxing Medical, a leading domestic enterprise in sports medicine Tianxing Medical was founded in 2017 and is a leading domestic enterprise in sports medicine, committed to providing comprehensive clinical solutions for sports medicine. Its products are used in sports medicine equipment, implants, and surgical instruments for shoulder joints, knee joints, foot/ankle joints, hip joints, elbow joints, and hand/wrist joints, with a total of more than 300 specifications approved by NMPA. They have been clinically applied in thousands ...
- Source: drugdu
- 382
- January 22, 2025
On the same day, the “twin giants” of insulin disclosed their performance forecasts, and Kangnuo and Nuocheng Jianhua jointly announced an authorized and licensed cooperation

On the same day, the “Double Heroes” of NO.1 insulin disclosed their performance forecast: Ganli Pharmaceutical “turned over”, and Tonghua Dongbao’s net profit sharply decreased On January 20th, Tonghua Dongbao released its performance forecast, expecting to achieve a net profit attributable to shareholders of the listed company of approximately 40.5277 million yuan in 2024, a decrease of approximately 1.127 billion yuan compared to the same period last year, a year-on-year decrease of approximately 96.53%. The main reason for the performance change is that during the reporting period, a new round of centralized insulin procurement began to be implemented in various provinces and cities across the country, and the bidding prices of the company’s insulin products have decreased to varying degrees, resulting in a decline in sales revenue. On the same day, Ganli Pharmaceutical also released its performance forecast, expecting to achieve a net profit attributable to the owners of the ...
- Source: drugdu
- 363
- January 22, 2025
Continuously optimistic about the innovative pharmaceutical industry

According to the AI News, CITIC Securities stated that policy support for innovative drugs is expected to further increase. In addition, the global sales of ADC drugs will reach 10.4 billion US dollars in 2023, and Chinese companies are accelerating their ADC layout and promotion, gradually ushering in a harvest period; The GLP-1 weight loss track has matured, and competition has shifted from single weight loss to multiple benefits. There are potential opportunities for new targets to go global; The IO multi antibody track AK112 has achieved a breakthrough, and TCE technology has moved from hematological tumors to solid tumors and self immunity. The global competitiveness of innovative drugs in China continues to strengthen, and the NewCo model has become a new choice for innovative drugs to go global. National policies encourage the development of innovative drugs, new technologies drive rapid industry growth, and new opportunities arise for going global. ...
- Source: drugdu
- 234
- January 22, 2025
Huadong Medicine’s exclusive marketing product Cenaparib Capsules (Paisuning®) has been approved for marketing by NMPA

Recently, Hangzhou Sino-US Huadong Pharmaceutical Co., Ltd. (hereinafter referred to as “Sino-US Huadong”), a wholly-owned subsidiary of Huadong Medicine Co., Ltd. (hereinafter referred to as “the Company”), has obtained the approval of the National Medical Products Administration (NMPA) for the exclusive marketing product Cenaparib Capsules (trade name: Paisuning®, research and development code: IMP4297) for marketing, which is used for maintenance treatment of adult patients with advanced epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer after achieving complete remission or partial remission of first-line platinum-containing chemotherapy. About Cenaparib On December 19, 2023, Sino-US Huadong and Shanghai Yingpai Pharmaceutical Co., Ltd. (hereinafter referred to as “Yingpai Pharmaceutical”), a wholly-owned subsidiary of Nanjing Yingpai Pharmaceutical Co., Ltd., signed an exclusive marketing service agreement. Sino-US Huadong obtained Yingpai Pharmaceutical’s exclusive marketing rights for Cenaparib in mainland China. Cenaparib is a novel, highly effective PARP1/2 inhibitor independently developed by Impa Pharmaceuticals. It has ...
- Source: drugdu
- 323
- January 22, 2025
Domestic new drugs are popular, and some people are falling behind

In the second half of 2024, domestic TCE bispecific antibody transactions are popular all over the world, and autoimmune-related transactions account for 5 of all 7 domestic TCE bispecific antibody transactions, which can be called the “hottest” type of domestic innovative drugs. It is in this wave of global pharmaceutical companies scrambling for autoimmune TCE bispecific antibody rights that some developers have begun to fall behind, and the most advanced overseas biotech company IGM Biosciences. On January 9, IGM Biosciences announced that the company will lay off 73% of its employees and stop developing two autoimmune candidate drugs, Imvotamab (CD3/CD20 bispecific antibody) and IGM-2644 (CD3/CD38 bispecific antibody). IGM made such a decision because its CEO Mary Beth Harler said that the interim data of the Phase Ib study of Imvotamab in the treatment of rheumatoid arthritis and systemic lupus erythematosus showed that the depth and consistency of B cell depletion ...
- Source: drugdu
- 262
- January 22, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.